CD200/BCL2 DP cases were more frequent among patients with WBC counts of <30x109/L (64/92, 69.5% vs. 79/150, 56.5%; p=0.04), in CD34+ AML (57/92, 62% vs. 64/150, 42.7% in CD34-negative patients; p=0.004), and in cases of NPM1-wt (71/88, 80.7% vs. 73/130, 35.9% in NPM1 mutated cases; p<0.001). This evidence concerns the gene CD34 and acute myeloid leukemia.